Modeling and Simulation - PK/PD Archives | Page 33 of 39

Publication

Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate

Twenty four hour ammonia profiles and correlates of drug effect were examined in a phase…

CertaraAugust 1, 2011

Knowledge Base

How Can PK/PD Analysis Add Value to Patient Care?

In May 2011, T.J. Smith and B.E. Hillner published an opinion piece in the New…

CertaraJuly 11, 2011

Knowledge Base

What is Curve Stripping?

The process of curve stripping is used in both compartmental and non-compartmental analysis. Each pharmacokinetic…

CertaraJuly 6, 2011

Publication

Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

The purpose of this study was to develop a pharmacokinetic-pharmacodynamic disease progression (PK/PD/DIS) model to…

CertaraJuly 1, 2011

Publication

Clinical Tolerance and Toxicity of Intravenous Baclofen: A Pilot Study in a Canine Model

Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Prospective pharmacokinetic study…

CertaraJuly 1, 2011

Publication

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

A model-based strategy was used to inform the early clinical development of anacetrapib, a novel…

CertaraJune 1, 2011

Publication

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients

TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of…

CertaraApril 12, 2011

Blog Knowledge Base

What to Do with Those BLQs!

BLQ values are like those pimples we used to get as teenagers. They…

CertaraApril 6, 2011

Blog Knowledge Base

The Difference Between Vd and Vss

There are many terms used to represent volume of distribution, but two common ones are…

CertaraMarch 31, 2011

Knowledge Base

What is Shrinkage?

In 2007, Mats Karlsson and Radojka Savic published a perspective in Clinical Pharmacology & Therapeutics…

CertaraMarch 29, 2011

Modeling and Simulation – PK/PD

Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate

How Can PK/PD Analysis Add Value to Patient Care?

What is Curve Stripping?

Pharmacokinetic-pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-induced Arthritis

Clinical Tolerance and Toxicity of Intravenous Baclofen: A Pilot Study in a Canine Model

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients

What to Do with Those BLQs!

The Difference Between Vd and Vss

What is Shrinkage?

Newsletter sign up

Quick links

Solutions

Contact